A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

VenoStent Embarks on Clinical Trial to Improve Success Rate of Vascular Surgery Outcomes

Successful enrollment in initial feasibility trial to support future regulatory submissions and provide better outcomes for patients with end-stage renal disease

VenoStent is a clinical-stage tissue engineering company developing tunable, bioabsorbable, smart polymer wraps to fundamentally transform the efficacy of the five million vascular surgeries performed each year, announces successful enrollment in its initial feasibility clinical trial.

The clinical trial is testing the safety and efficacy of its 3D-printed bioabsorbable wraps in humans, a new methodology to improve surgical outcomes for hemodialysis patients.

“We are very pleased to announce that we have successfully enrolled twenty end-stage renal disease patients in our initial feasibility study taking place in Asuncion, Paraguay,” says Tim Boire, CEO. “After years of development, we are confident that our bioabsorbable wrap technology can have a positive impact on the lives of patients that require hemodialysis to sustain life. This is a major milestone toward our mission to improve the quality and length of life for end-stage renal disease patients, as well as others needing vascular surgery.”

Feasibility Study

Enrollment was completed for the initial VenoStent Feasibility Study in Paraguay involving 20 end-stage renal disease patients that were referred for creation of an arteriovenous fistula—surgical connection of an artery to a vein in the arm—to enable hemodialysis treatments. The participants in the study are followed up for several months and the team has already seen highly encouraging safety and performance signals, which could indicate much greater clinical outcomes and quality of life for kidney disease patients when treated with the VenoStent SelfWrap® Bioabsorbable Perivascular Wrap technology.

Approximately 60% of the blood vessels used for dialysis, and 20% of the blood vessels used for quadruple bypass, fail within 12 months of the vascular surgery, risking the lives of 5 million patients every year. The reason for this 60% failure rate is that the vein is not accustomed to, nor equipped for, the high pressure, high flow arterial environment. The thin-walled vein expands, causing tearing of the protective inner lining of the vein. In response to this expansion and tearing, the cells inside the vein wall begin a repair process and migrate inward. This remodeling and cell growth response (also called neointimal hyperplasia) ultimately leads to reduction in, or complete blockage of, blood flow. VenoStent’s proprietary bioabsorbable scaffold goes around these blood vessels at the time of vascular surgery to aid in their “arterialization” process. To make its implantable smart polymer wraps, VenoStent utilizes advanced stereolithography fabrication with 3D printers supplied by Volumetric, a fellow Houston alum of the California-based accelerator Y Combinator.

 

SourceVenoStent
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy